Paclitaxel

Generic Name
Paclitaxel
Brand Names
Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
Drug Type
Small Molecule
Chemical Formula
C47H51NO14
CAS Number
33069-62-4
Unique Ingredient Identifier
P88XT4IS4D
Background

Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication

Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions
Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
Associated Therapies
-
Clinical Trials
Related News

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

First Posted Date
2023-04-24
Last Posted Date
2024-11-25
Lead Sponsor
GI Innovation, Inc.
Target Recruit Count
358
Registration Number
NCT05824975
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

🇺🇸

Mayo Clinic in Minnesota, Rochester, Minnesota, United States

and more 7 locations

AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

First Posted Date
2023-04-24
Last Posted Date
2024-10-02
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
36
Registration Number
NCT05826015
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

🇺🇸

University of California, San Francisco, San Francisco, California, United States

🇺🇸

University of Oklahoma, Oklahoma City, Oklahoma, United States

and more 1 locations

Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma

First Posted Date
2023-04-20
Last Posted Date
2023-04-20
Lead Sponsor
Fujian Medical University Union Hospital
Target Recruit Count
40
Registration Number
NCT05821452
Locations
🇨🇳

Fujian Medical University Union Hospital, Fuzhou, China

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

First Posted Date
2023-04-19
Last Posted Date
2024-06-04
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
21
Registration Number
NCT05819892
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer

First Posted Date
2023-04-12
Last Posted Date
2023-07-24
Lead Sponsor
Novartis Pharmaceuticals
Registration Number
NCT05809895

Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma

First Posted Date
2023-04-05
Last Posted Date
2024-11-08
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
24
Registration Number
NCT05799612
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

First Posted Date
2023-04-05
Last Posted Date
2023-04-05
Lead Sponsor
Guangzhou Gloria Biosciences Co., Ltd.
Target Recruit Count
424
Registration Number
NCT05798819
Locations
🇨🇳

Fudan University Shanghai Cancer Hospital, Shanghai, Shanghai, China

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

First Posted Date
2023-04-05
Last Posted Date
2024-03-26
Lead Sponsor
Fox Chase Cancer Center
Target Recruit Count
280
Registration Number
NCT05800587
Locations
🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

First Posted Date
2023-04-05
Last Posted Date
2024-11-14
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
950
Registration Number
NCT05800015
Locations
🇺🇸

Crosson Cancer Institute, Fullerton, California, United States

🇺🇸

University of Illinois, Chicago, Illinois, United States

🇺🇸

Arizona Clinical Research Center, Tucson, Arizona, United States

and more 67 locations

Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer

First Posted Date
2023-04-03
Last Posted Date
2023-07-20
Lead Sponsor
Aston Sci. Inc.
Target Recruit Count
98
Registration Number
NCT05794659
Locations
🇺🇸

University of Washington, Seattle, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy